Abstract Number: 0552 • ACR Convergence 2020
Fast Food Habits and Serum Urate Change in Young Adults: 15-Year Prospective Cohort Analysis
Background/Purpose: Fast food consumption has strong positive associations with weight gain and insulin resistance. Obesity and insulin resistance are, in turn, strongly associated with elevated…Abstract Number: 0658 • ACR Convergence 2020
Identification of Two Novel Dysfunctional Variants in a Physiologically Important Urate Transporter ABCG2 in Paediatric-onset Familial Hyperuricemia and Gout Patients in Three Generations
Background/Purpose: ABCG2 is a high-capacity urate transporter gene. Common dysfunctional variants of ABCG2 that result in decreased urate excretion in humans are major causes of…Abstract Number: 0664 • ACR Convergence 2020
Uric Acid Level Is Associated with Severity of Heart Failure with Preserved Ejection Fraction
Background/Purpose: Hyperuricemia (HUC) has been shown to have an impact in the left atrium and left ventricle remodeling leading to the development of heart failure…Abstract Number: 0667 • ACR Convergence 2020
Gout Management Beyond Prescription Writing: The Role of the Pharmacist
Background/Purpose: Urate lowering therapy (ULT) is recommended for long-term gout management. However, gout flares are common at the time of starting ULT, and these flares…Abstract Number: 0674 • ACR Convergence 2020
Disease Control of Hyperuricemia Newly Detected by Medical Check-up: A Retrospective Cohort Study of Health Insurance Claims Data in Japan
Background/Purpose: Japanese guidelines for managing gout and hyperuricemia recommend the initiation of urate-lowering therapy (ULT) to prevent gouty arthritis in subjects having asymptomatic hyperuricemia with…Abstract Number: 0675 • ACR Convergence 2020
AR882, a Potent and Selective Uricosuric Agent, Significantly Reduced Serum Urate Levels Following Multiple Ascending Once-Daily Doses in Healthy Subject Volunteers
Background/Purpose: AR882 is a potent and selective uric acid transporter 1 (URAT1) inhibitor under development for the treatment of hyperuricemia or gout. AR882 exhibited linear…Abstract Number: 0685 • ACR Convergence 2020
The Impact of Azathioprine on the Frequency of Persistent Responsiveness to Pegloticase in Patients with Chronic Refractory Gout
Background/Purpose: Pegloticase is a mammalian recombinant uricase coupled to monomethoxy polyethylene glycol that is approved in the US for treatment of patients with chronic refractory…Abstract Number: 1221 • 2019 ACR/ARP Annual Meeting
Impact of Psoriasis Disease Activity and Other Risk Factors on Serum-urate Levels in Patients with Psoriasis and Psoriatic Arthritis – A Post-hoc Analysis of Pooled Data from Three Phase 3-trials with Secukinumab
Background/Purpose: Increased serum uric acid (sUA), hyperuricemia, has been reported to be associated with psoriasis (1). Increased cell turnover in psoriatic skin lesions has been…Abstract Number: 1223 • 2019 ACR/ARP Annual Meeting
Enteral Administration of ALLN-346, a Recombinant Urate-degrading Enzyme, Decreases Serum Urate in a Pig Model of Hyperuricemia
Background/Purpose: Uric acid homeostasis is determined as a balance between production, intestinal secretion and renal excretion. Around 2/3 of uric acid is excreted by the…Abstract Number: 1229 • 2019 ACR/ARP Annual Meeting
AR882, a Potent and Selective Uric Acid Lowering Agent Acting Through Inhibition of Uric Acid Reuptake, Shows Excellent Pharmacokinetics and Pharmacodynamics in a Phase 1 Clinical Trial
Background/Purpose: AR882 is a potent and selective uric acid transporter 1 (URAT1) inhibitor under development for the treatment of hyperuricemia or gout. A Phase 1…Abstract Number: 1233 • 2019 ACR/ARP Annual Meeting
Identification and Characterization of a Novel Dysfunction Variant p.I242T in ABCG2 Transporter in a Family with Early-onset Hyperuricamia and Gout
Background/Purpose: ABCG2 is a high-capacity urate transporter gene. Common dysfunctional variants of ABCG2 that result in decreased urate excretion in humans are major causes of…Abstract Number: 1234 • 2019 ACR/ARP Annual Meeting
Inconsistency in Uric Acid Reference Ranges Among 20 Top United States Hospitals: What Is “Normal”?
Background/Purpose: Elevated serum uric acid (UA) concentration is associated with the urate crystal deposition disorders gout and nephrolithiasis, as well as hypertension, the metabolic syndrome,…Abstract Number: 2051 • 2019 ACR/ARP Annual Meeting
Factors in Achieving Serum Uric Acid Target and the Occurrence of Gouty Arthritis: A Cross-sectional Study Based on Japanese Health Insurance Claim Data
Background/Purpose: The number of gout attacks can be reduced by achieving and maintaining serum uric acid (sUA) at or below 6.0 mg/dL, a level uniformly…Abstract Number: 2065 • 2019 ACR/ARP Annual Meeting
Association Between Anemia and Hyperuricemia: Korean National Health and Nutrition Survey 2016-2017
Background/Purpose: Hyperuricemia and anemia may be related in terms of sharing comorbidities such as chronic kidney disease (CKD) and cardiovascular disease. However, to our knowledge,…Abstract Number: 2077 • 2019 ACR/ARP Annual Meeting
Population Impact Attributable to Modifiable Risk Factors for Hyperuricemia and the Fallacy of the Variance Explained
Background/Purpose: In a seminal BMJ paper (Prior 1986), the Tokelau Island migrant study for gout and hyperuricemia concluded preventive strategies to modify body mass, diet…
- 1
- 2
- 3
- …
- 5
- Next Page »